CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)-T细胞疗法正在成为某些血液系统恶性肿瘤治疗的重要手段。虽然CAR-T 细胞在某些血液系统恶性肿瘤中产生了强有力的应答,但与治疗相关的毒性限制了其应用。免疫效应细胞相关神经毒性综合征(ICANS)是一种可能危及生命的神经毒性,常发生于CAR-T 细胞治疗中。在此,我们将讨论ICANS、其治疗、可能的机制以及针对CAR-T 细胞疗法这一关键局限性的潜在解决方案。随着CAR-T 细胞疗法领域的发展,需要改进治疗方法和策略以规避或克服ICANS,从而改善发病率、死亡率并降低CAR-T 细胞疗法的成本。这种严重的、危及生命的副作用需要被研究,以更好地理解其机制并开发治疗方法和替代策略。
Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy have limited their use. Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) is a potentially life-threatening neurotoxicity that commonly occurs with CAR-T cell therapy.
Here we will discuss ICANS, its treatment, possible mechanisms, and potential solutions to this critical limitation of CAR-T cell therapy. As the field of CAR-T cell therapy evolves, improved treatments and methods to circumvent or overcome ICANS are necessary to improve morbidity, mortality, and decrease the cost of CAR-T cell therapy. This serious, life-threatening side effect needs to be studied to better understand its mechanisms and develop treatments and alternative strategies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。